News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Symphogen A/S Release: Sym004 Advances Into Two New Clinical Trials And Receives Milestone Payments



8/7/2014 10:08:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

COPENHAGEN, Denmark--(BUSINESS WIRE)--Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that its collaborative partner, Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, Merck Serono has initiated two new clinical studies evaluating Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR). The trials are a Phase 2b study in patients with metastatic colorectal cancer (mCRC) and a Phase 1b study in patients with Non-Small Cell Lung Cancer (NSCLC). Symphogen also reports that it is eligible to receive two milestone payments from Merck for achieving certain agreed goals in the collaboration, related to the bi-weekly dosing study and the mCRC study.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES